Why ViewpointMT? Discussing the pending merger, #Isoray CEO Lori Woods explains the due diligence process and what it revealed. #cancer #oncology #Radiopharmaceuticals #Radiotherapy #radiation #brachytherapy

.Isoray CEO Lori Woods describes the common beliefs and business synergy important to the reasoning behind the pending merger with ViewpointMT. #cancer #oncology #Radiopharmaceuticals #Radiotherapy #Isoray #radiation #brachytherapy

.Isoray CEO Lori Woods discussed the shared approach to inside-out #cancer treatment and its importance in the the recent webcast on the pending merger with ViewpointMT. #oncology #Radiopharmaceuticals #Radiotherapy #radiation #brachytherapy

Read his blog and see why leading Medical Physicist Peter T. Heiberger, M.S. DABR, RSO Aurora Health Care believes Cesium-131 is the better choice for #prostatecancer #brachytherapy. bit.ly/3h3SxBF #cancer #oncology #radiation #medicaltechnology

See Isoray CEO Lori Woods with Proactive USA financial media discussing the transformational opportunity in the company’s pending merger with ViewpointMT. bit.ly/3BkxxgP $ISR #oncology #investors #medicaltechnology #radiation #radiopharmaceuticals

. ViewpointMT CEO Thijs Spoor gave an overview of the innovative company in the recent webcast on its pending merger with #Isoray. Here’s what he said about the innovative company. #oncology #Radiopharmaceuticals #radiation #Radiotherapy #cancer

Did you watch #Isoray CEO Lori Woods with Proactive financial media discussing the Isoray merger with Viewpoint Molecular Targeting, Inc. and the big opportunity it represents in 2023? bit.ly/3BkxxgP #oncology #Radiopharmaceuticals #radiation #Radiotherapy #cancer

Read CEO Lori Woods’ end of year blog post looking to the future and the exciting potential in the pending #Isoray-ViewpointMT merger. bit.ly/3YrlckN #oncology #investors #radiotherapy #radiopharmaceuticals #cancer #radiation

Have you looked at how the pending Isoray -ViewpointMT came together? #Isoray CEO Lori Woods explains the due diligence process and what it showed. #oncology #investors #radiotherapy #radiopharmaceuticals #cancer #radiation

Don’t miss CEO Lori Woods’ end of year blog post looking to the future and the exciting potential in the pending #Isoray - ViewpointMT merger. bit.ly/3YrlckN #oncology #investors #radiotherapy #radiopharmaceuticals #cancer #radiation

Did you listen to ViewpointMT CEO Thijs Spoor give an overview of the innovative company in the recent webcast on its pending merger with #Isoray? Here’s what he said about the innovative company. #oncology #Radiopharmaceuticals #radiation #Radiotherapy #cancer

ICYMI: Isoray CEO Lori Woods looked at the inside-out #cancer treatment approach and its importance in the pending merger with ViewpointMT. #oncology #investors #brachytherapy #oncology #radiopharmaceuticals #medicaltechnology #radiotherapy

Have you read about ViewpointMT’s targeted #cancer therapies and pipeline? Take a look. bit.ly/3Zp7jEu #oncology #investors #brachytherapy #oncology #radiopharmaceuticals #medicaltechnology #radiotherapy

.@ViewPoint_MT announces their lead drug for neuroendocrine tumors was administered to patients in India. Here are the details. bit.ly/3XJlP8w #cancer #oncology #radiotherapy #radiopharmaceuticals

.Isoray today announced stockholders approved a proposal allowing the Company to consummate the proposed merger with ViewpointMT. Here are the details. bit.ly/40caobh #cancer #oncology #radiotherapy #radiopharmaceuticals #radiation

.Isoray today announced the successful completion of the merger with ViewpointMT. Viewpoint Molecular Targeting, Inc. revealing the combined companies’ new leadership, focus, board of directors, and more. bit.ly/3X8cNB7 #cancer #radiotherapy #radiopharmaceuticals

#Isoray, Inc. and its newly merged partner ViewpointMT, has announced a corporate name change to Perspective Therapeutics Inc, a new brand identity and more. Here are all the details. bit.ly/3DQSNft #cancer #radiotherapy #radiopharmaceuticals #radiation

A presentation on initial results of patient data from compassionate use of Perspective Therapeutics’ lead preclinical candidate for neuroendocrine tumors being used in India shows extremely encouraging results. bit.ly/3SosaEB #cancer #radiotherapy #radiopharmaceuticals